# GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

> **NCT01257802** · PHASE3 · TERMINATED · sponsor: **Joseph Mccune** · enrollment: 14 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic
- Systemic Vasculitis
- Isolated Angiitis of Central Nervous System
- Lung Disease With Systemic Sclerosis
- Lung Disease Interstitial Diffuse

## Interventions

- **DRUG:** depot leuprolide acetate 3.75 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01257802
- **Lead sponsor:** Joseph Mccune
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-06-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257802, "GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01257802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*